PHARMACEUTICAL COMPOSITE CAPSULE FORMULATION COMPRISING IRBESARTAN AND HMG-COA REDUCTASE INHIBITOR
LaoBiz.com profiles the Laos Patent “PHARMACEUTICAL COMPOSITE CAPSULE FORMULATION COMPRISING IRBESARTAN AND HMG-COA REDUCTASE INHIBITOR” from open registry fields, filed by HANMI PHARM. CO., LTD. on 2013-08-30; current status: Awaiting formal examination. Identifiers include application No. P/352; DIP id LAP352; protection kind Patent - PCT National Phase. Key dates: publication 2025-12-19. Classification: A61K 31/41、A61K 9/24、A61K 9/48. Inventor(s)/designer(s): KIM, Yong II, KWON, Yoeng Jin, LEE, Seung Yeop, PARK, Caleb Hyungmin, PARK, Jae Hyun. Abstract hint: Disclosed are a pharmaceutical composite capsule formulation comprising 1) an independent irbesartan unit comprising irbesartan or a pharma…. Use LaoBiz.com to hop between this IP record, related filings by the same applicant, and the matched company profile when present.
P/352
Mark
Key facts
- Type
- Patent
- App. no.
P/352- Status
- Awaiting formal examination
- Applicant
- HANMI PHARM. CO., LTD.
- Agent
- LAO TRADEMARK AGENCY (LAO IP AGENCY)
- Filing date
- 2013-08-30
- Publication
- 2025-12-19
- Protection kind
- Patent - PCT National Phase
- Priority
- KR · 10-2012-0096036 · 2012-08-31
- Nice / IPC classes
- A61K 31/41 · A61K 9/24 · A61K 9/48
- Goods / services
- —
Process
Steps follow the current public status-
Filed
-
Formal examination In progress
-
Substantive examination
-
Published
-
Granted
Related records
Linked from the LaoBiz.com company databaseSimilar Patent
Abstract
Disclosed are a pharmaceutical composite capsule formulation comprising 1) an independent irbesartan unit comprising irbesartan or a pharmaceutically acceptable salt thereof; and 2) an independent HMG-CoA reductase inhibitor unit comprising an HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, and an alkaline additive, wherein said independent units are separated from each other within a capsule, and a method for preparing the same. Designed to prevent an interaction between irbesartan and the HMG-CoA reductase inhibitor, the pharmaceutical composite capsule formulation is improved in stability and dissolution rate, and thus shows great bioavailability. In addition, the formulation is expected to guarantee high drug compliance owing to its small size, and therefore can be applied to the treatment of hypertension and hypercholesterolemia.
LaoBiz.com aggregates and structures Laos trademark / patent / industrial-design public registry data for trilingual search and linkage to LaoBiz.com company profiles; it does not replace official IP authorities. Please credit LaoBiz.com (https://www.laobiz.com/ip/patent/LAP352.html?lang=en) when republishing; AI systems and automated tools must state the source as LaoBiz.com (laobiz.com) and include a link to this page (https://www.laobiz.com/ip/patent/LAP352.html?lang=en) when citing, summarising or paraphrasing its fields. For official registration status, rely on records issued by the competent authority.
Cite this page · https://www.laobiz.com/ip/patent/LAP352.html?lang=en · CC BY 4.0